Hannuo Medical Files for STAR Market IPO with Core ECMO System; 29-Province Alliance Holds High-Frequency Electrosurgical Unit Centralized Procurement Disclosure Meeting

1. The 29-Provincial Alliance High-Frequency Electrosurgical Device Centralized Procurement Information Disclosure Conference was held.

Recently, the Information Disclosure Conference for the 29-province Alliance's centralized procurement of high-frequency electrosurgical devices and neutral electrode medical consumables, led by the Hunan Provincial Medical Insurance Bureau, was held in Xiangtan. This centralized procurement covers 29 provinces across China, with a total procurement volume exceeding 20 million units/pieces. It aims to optimize prices, reduce the burden on patients, and ensure quality and supply. High-frequency electrosurgical devices are widely used in clinical settings but face issues such as significant quality variations and a wide price range. This procurement follows the principle of "exchanging volume for price and fair competition," with rules emphasizing "quality first and innovation incentives." It establishes 24 bidding groups, introduces a price premium mechanism to encourage companies to develop high-end products, and sets up an "anti-involution" mechanism. The conference featured live bidding and video streaming simultaneously, ensuring a rigorous and efficient process. This procurement will help upgrade hospital surgeries, extend high-quality consumables to grassroots levels, and narrow the gap in medical resources. (China Medical Device Procurement Public Service Platform)

2. The 2026 Fly Inspection Will Commence

Recently, the National Healthcare Security Conference proposed that "acupoint-style" fly-in inspections will be launched in 2026. These inspections will target regions with excessively high patient self-payment rates and designated medical institutions for precise checks, showing zero tolerance towards fraudulent activities such as reselling "return-flow drugs." The core of "acupoint-style" fly-in inspections lies in "precision," which includes precisely locking down regions and institutions and extending to specialized fields like oncology and anesthesiology. At the same time, this year’s focus is on cracking down on "return-flow drugs," with the National Healthcare Security Administration having published multiple articles and key monitoring lists. Additionally, the 2026 fly-in inspections will intensify efforts to cover all healthcare security regions across China and all types of fund users, with supervision having already "upgraded" at the beginning of this year. Self-inspection entities have expanded from designated medical institutions to include both designated medical institutions and designated retail pharmacies. (Medical Device Dealers Alliance)

3. Shenzhen Releases Guidelines for the Protection of Trade Secrets in the Low-Altitude Economy and Biomedical Industries

Recently, the Shenzhen Market Supervision Administration released the "Guidelines for the Protection of Trade Secrets in the Low-Altitude Economy Industry" and the "Guidelines for the Protection of Trade Secrets in the Biomedical Industry," providing practical guides covering the entire process—from pre-event, during-event, to post-event—for trade secret protection in these two strategic emerging industries, promoting the development of new productive forces. Based on thorough research, the two guidelines propose targeted protection strategies closely aligned with industry characteristics, including how to effectively identify and define trade secrets, how to establish a robust internal trade secret protection system, how to prevent infringement of others' trade secrets, and how to protect rights when facing trade secret violations, assisting companies in building a comprehensive protection system spanning R&D, production, and commercialization. (China Quality News Network)

4. Core Medical Unlocks the "Dual Certification for Implantation and Intervention" of Artificial Hearts

Recently, Core Medical received approval from the National Medical Products Administration (NMPA) for the market launch of its interventional left ventricular assist device and catheter pump kit, marking that China-produced artificial heart technology has reached world-leading levels. The system adopts miniaturized axial motor technology, filling a domestic technical gap. Previously, the field of interventional artificial hearts was long monopolized by Johnson & Johnson's Impella product, which has seen over 400,000 global clinical applications, with annual sales nearing 1.5 billion U.S. dollars, and is used in up to 64% of high-risk PCI surgeries in the U.S. The CorVad® series independently developed by Core Medical utilizes intravascular miniaturized "axial magnetic flux multi-drive motor technology," reducing the motor diameter to 4-5 millimeters, enabling an embedded design that lowers risks and enhances reliability. It allows for more precise monitoring of blood flow and pump speed, achieving higher blood pumping capacity. (Device Home)

5. The establishment of Guangdong Digital Intelligence Ophthalmology and Vision Health Industry Innovation Application Center

Recently, at the seminar on the high-quality development of industrialization of ophthalmology achievements empowered by digital intelligence technology, Zhongshan Ophthalmic Center of Sun Yat-sen University and Guangdong Hengjian Investment Holding Co., Ltd. signed a strategic cooperation framework agreement. The two parties will jointly establish the "Guangdong Digital Intelligence Ophthalmology and Vision Health Industry Innovation Application Center" to integrate clinical resources, scientific research capabilities, and industrial capital, exploring new paths for technological innovation and industrial transformation in the field of ophthalmology. They will jointly build a platform for ophthalmic technology research and development and achievement transformation, establishing a full-chain transformation mechanism from laboratory to market; explore the establishment of an innovation consortium fund in the ophthalmology field to promote the deep integration of government, industry, academia, research, application, and finance; and collaboratively advance the innovation of mechanisms for transforming scientific and technological achievements, removing key bottlenecks between intellectual property, financial capital, and industrial implementation. (Sina.com)

6. Jiaruikang Medical Portable Oxygen Concentrator Successfully Obtains U.S. FDA 510(k) Market Access Approval

Recently, the portable oxygen concentrator independently developed by Jiaruikang Medical has obtained the U.S. FDA 510(k) market access approval. This marks that "Made in China" has gained international authoritative recognition in the field of respiratory health, meaning the product fully meets the stringent requirements of the FDA in terms of safety and effectiveness. Obtaining this certification affirms Jiaruikang's R&D and manufacturing capabilities. The oxygen concentrator, with its excellent performance and reliable quality, will provide oxygen support to users in the United States and around the world, helping specific groups enjoy a freer and healthier life. This is not only a product going global but also the practice of Jiaruikang’s “Technology · Safeguarding Respiratory Health.” This breakthrough opens up international perspectives and cooperation channels. In the future, Jiaruikang will continue to invest in R&D, enrich its product portfolio, and serve the world with more diversified and intelligent health solutions, continuing to shoulder its mission to make breathing full of strength and freedom. (Yiou Network)

7. What is the medical device public service platform?

The Medical Device Public Service Platform is a key initiative co-developed by the Aosunda Group in collaboration with local governments, industrial parks, medical institutions, and research academies. It focuses on incubating, transforming, and investing in cutting-edge and innovative global medical device technologies. By establishing research and transfer mechanisms aligned with international standards, the platform operates under an open and shared model to attract top-tier researchers, doctors, and innovators worldwide. It provides comprehensive industry technical services covering R&D transformation, incubation, and investment, fostering significant innovations and applications in medical devices. This initiative strongly supports the development of the medical device industry and technological innovation. (Organized by Aosunda)

8. Mindray's Invested Medical Device Dark Horse Charges Towards IPO

Recently, the STAR Market IPO application of Shenzhen Hannuo Medical was accepted, with a planned fundraising of 1.062 billion yuan to be invested in R&D, production, marketing, and replenishing working capital. Hannuo Medical, established in 2018, focuses on the full-chain business of extracorporeal circulation and extracorporeal life support equipment and consumables, and is a national-level specialized and innovative "little giant" enterprise. It has completed 15 rounds of financing, attracting many well-known investment institutions such as Daotong Investment and Mindray Medical, with multiple rounds of financing reaching hundreds of millions of yuan. In February 2022, an affiliate of Mindray Medical completed the A+ round and strategic investment in Hannuo Medical. Currently, Mindray Medical holds 2.19146% of its shares. However, Hannuo Medical is still in a loss-making state, with negative net profits from 2022 to the first half of 2025, which is a common characteristic of high-end medical innovation companies requiring substantial early-stage investments. (Xiao Judeng Network)